Kodiak Sciences Files Q1 2025 10-Q
Ticker: KOD · Form: 10-Q · Filed: May 14, 2025 · CIK: 1468748
| Field | Detail |
|---|---|
| Company | Kodiak Sciences Inc. (KOD) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech, drug-development
TL;DR
Kodiak Sciences Q1 2025 10-Q filed. Financials and program expenses updated.
AI Summary
Kodiak Sciences Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information including program expenses for KSI-501 and KSI-101, and Tarcocimab. It also reports on equity components like Additional Paid-In Capital and Retained Earnings as of March 31, 2025.
Why It Matters
This filing provides investors with an update on Kodiak Sciences' financial position and operational expenses for its key drug development programs in early 2025.
Risk Assessment
Risk Level: medium — Biotech companies like Kodiak Sciences are inherently risky due to the high cost and uncertainty of drug development.
Key Numbers
- 2025-03-31 — Reporting Period End Date (The 10-Q covers financial activities up to this date.)
- 2025-01-01 — Reporting Period Start Date (The 10-Q covers financial activities from this date.)
Key Players & Entities
- Kodiak Sciences Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- KSI-501 (drug_program) — Program expense mentioned
- KSI-101 (drug_program) — Program expense mentioned
- Tarcocimab (drug_program) — Program expense mentioned
FAQ
What were the specific program expenses for KSI-501 and KSI-101 during the first quarter of 2025?
The filing indicates program expenses for KSI-501 and KSI-101 for the period January 1, 2025 to March 31, 2025, but specific dollar amounts are not detailed in the provided snippet.
What is the total amount of Additional Paid-In Capital as of March 31, 2025?
The filing references 'us-gaap:AdditionalPaidInCapitalMember' for the period ending March 31, 2025, but the specific dollar value is not present in the provided text.
What were the Retained Earnings as of December 31, 2023?
The filing shows 'us-gaap:RetainedEarningsMember' for December 31, 2023, but the specific dollar amount is not included in the provided snippet.
Does the filing mention any fair value measurements for recurring items as of March 31, 2025?
Yes, the filing references 'us-gaap:FairValueMeasurementsRecurringMember' and 'us-gaap:FairValueInputsLevel1Member' for March 31, 2025, and also 'us-gaap:MoneyMarketFundsMember' within recurring fair value measurements.
What is the company's fiscal year end?
Kodiak Sciences Inc.'s fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Kodiak Sciences Inc. (KOD).